Axolabs GmbH Revenue and Competitors

Kulmbach, ger

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Axolabs GmbH's estimated annual revenue is currently $27.4M per year.(i)
  • Axolabs GmbH's estimated revenue per employee is $155,000

Employee Data

  • Axolabs GmbH has 177 Employees.(i)
  • Axolabs GmbH grew their employee count by 33% last year.

Axolabs GmbH's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$32.6M2108%N/AN/A
#2
$14.3M92-12%N/AN/A
#3
$11.5M7410%N/AN/A
#4
N/A5969%N/AN/A
#5
N/A5893%N/AN/A
#6
$27.4M17733%N/AN/A
Add Company

What Is Axolabs GmbH?

Axolabs, a growing company located in Kulmbach (Bavaria, Germany) and Berlin, is a member of the globally active LGC Group. As the world’s leading Custom Research Organization (CRO) in the field of DNA-/RNA-based therapeutics we are committed to the development of innovative drugs. We offer a broad range of services for therapeutic oligonucleotides and mRNAs covering bioinformatics, chemical synthesis of oligonucleotides, oligonucleotide conjugates and formulations, analytics, bioanalytics, in vitro and in vivo testing. Due to 21 years of experience in the field we are well known from big pharma and biotech to academia and venture capital for our profound knowledge, high quality standards and excellent research.\n\nThe recently founded Axolabs Berlin GmbH is newly established as a contract manufacturer (GMP) for chemical DNA/RNA therapeutics in Berlin. The LGC Group is thus expanding its expertise in the field of nucleic acid-based therapeutics, which are currently already bundled in the companies Axolabs GmbH, Kulmbach, and LGC Biosearch Technologies, Petaluma, USA. \n\nServices: bioinformatics, oligonucleotide synthesis, analytics and in vitro / in vivo analysis.

keywords:N/A

N/A

Total Funding

177

Number of Employees

$27.4M

Revenue (est)

33%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$50.6M21910%N/A